secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001099800-22-000023
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q3 sales $1.32B; adjusted EPS $0.61 (up 13% YoY); cuts FY22 adjusted EPS guidance to $2.40-$2.50
--------------------------------------------------------------------------------

- GAAP EPS $0.55, adjusted EPS $0.61; $0.07/share charge from discontinuing HARPOON surgical mitral repair.
- TAVR sales $862M (+1% reported, +6% cc); TMTT sales $30M; U.S. procedures grew mid-single digits YoY.
- 2022 adjusted EPS guidance revised to $2.40-$2.50 from prior $2.50-$2.65 range; total sales now expected at low end of $5.35-$5.55B.
- Received U.S. FDA and CE Mark for PASCAL Precision; U.S. FDA approval for SAPIEN 3 Ultra RESILIA valve.
- Q3 free cash flow $250M; cash and investments $1.7B as of Sept. 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/0001099800-22-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/ew-20221027.htm
  HTML page:      https://secwatch.observer/filing/0001099800-22-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer